CORRECTING and REPLACING Syros to Present at 39th Annual J.P. Morgan Healthcare Conference
Get Alerts SYRS Hot Sheet
Join SI Premium – FREE
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Conference date in details should read: Thursday, January 14 (instead of Thursday, January 7)
The updated release reads:
SYROS TO PRESENT AT 39TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will present a corporate overview at the virtual 39th Annual J.P. Morgan Healthcare Conference. Details are as follows:
39th Annual J.P. Morgan Healthcare Conference:
Date: Thursday, January 14
Time: 2:50 p.m. ET
A live webcast of the presentation will be available on the Investors & Media section of the Syros website at www.syros.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.
About Syros Pharmaceuticals
Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Syros is advancing a robust clinical-stage pipeline, including SY-1425, a first-in-class oral selective RARα agonist in RARA-positive patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia, SY-2101, a novel oral form of arsenic trioxide in patients with acute promyelocytic leukemia, and SY-5609, a highly selective and potent oral CDK7 inhibitor in patients with select solid tumors. Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases. For more information, visit www.syros.com and follow us on Twitter (@SyrosPharma) and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210107005054/en/
Media Contact:
Naomi Aoki
Syros Pharmaceuticals
617-283-4298
[email protected]
Investor Contact:
Hannah Deresiewicz
Stern Investor Relations, Inc.
212-362-1200
[email protected]
Source: Syros Pharmaceuticals
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Renesas Announces Consolidated Forecasts
- ROSEN, LEADING INVESTOR COUNSEL, Encourages Doximity, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – DOCS
- TransAlta Declares Dividends
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
JPMorgan, TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!